Begin main content

Keytruda for Metastatic Urothelial Carcinoma – Details

Project Number pCODR 10117
Brand Name Keytruda
Generic Name Pembrolizumab
Tumour Type Genitourinary
Indication Metastatic Urothelial Carcinoma
Funding Request For the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received platinum-containing chemotherapy
Review Status Pending
Pre Noc Submission Yes
NOC Date
Manufacturer Merck Canada Inc.
Submitter Merck Canada Inc.
Submission Date (Target Date) July 24, 2017
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ August 8, 2017
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.